Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure

PAUL DALY, JEAN-LUCIEN ROULEAU, DANIEL COUSINEAU, JOHN H BURGESS, KANU CHATTERJEE*

From the Cardiovascular Division and the University Medical Clinics, Montreal General Hospital, McGill University, Montreal, Canada; and *Cardiovascular Division, Department of Medicine, University of California, San Francisco, California, USA

SUMMARY Changes in circulating catecholamines and transmyocardial catecholamine balance associated with improved left ventricular function were studied in patients with chronic heart failure after treatment with captopril (10 patients) and hydralazine in combination with isosorbide dinitrate (eight patients). Cardiac performance improved in response to both captopril and hydralazine-nitrate treatment. The systemic haemodynamic effects were also qualitatively similar, but the hydralazine-nitrate combination caused a greater increase in cardiac index and heart rate. Captopril did not change arterial adrenaline concentrations (0.63 to 0.60 nmol/l), arterial noradrenaline (4.2 to 3.9 nmol/l), or net transmyocardial noradrenaline release (390 to 317 pmol/min), while hydralazine-nitrate increased arterial adrenaline (0.91 to 1.47 nmol/l) and transmyocardial noradrenaline release (225 to 554 pmol/min).

Although both captopril and hydralazine-nitrate treatment improve left ventricular performance in patients with chronic heart failure, hydralazine-nitrate enhances cardiac sympathetic tone and captopril does not. The clinical relevance of these findings, however, is not known.

Captopril and the combination of hydralazine and isosorbide dinitrate are two vasodilator drug regimens which are frequently used to treat patients with congestive heart failure. They have significantly different systemic haemodynamic effects, but the mechanisms for these remain unclear. We and others have postulated that these differences may be related to the different effects of these drugs on cardiac sympathetic tone.

In patients with heart failure, captopril has been shown to reduce circulating noradrenaline concentrations, while the effects of hydralazine have been variable. In order to measure in vivo cardiac sympathetic activation it is necessary to measure not only arterial adrenaline and noradrenaline concentrations but also cardiac catecholamine balance. We administered captopril or a combination of hydralazine and isosorbide dinitrate to 18 patients with congestive heart failure associated with coronary artery disease. We measured arterial adrenaline, arterial noradrenaline, and transmyocardial catecholamine balance before and after these interventions. Changes in systemic and coronary haemodynamic function were also assessed concurrently.

Patients and methods

Twenty one consecutive patients (16 male and five female) with chronic congestive heart failure associated with coronary artery disease who did not respond to digoxin and diuretic treatment were screened for this study. Three patients were...
Excluded—two because of hypertension (mean arterial pressure of 136 and 138 mm Hg), and one patient because of a stroke work index > 35 g m/min. The remaining 18 patients enrolled in the study were 46–83 years old and had not experienced an acute ischaemic event for at least three months. In eight of the 18 patients coronary artery disease had been proved by selective coronary arteriography. The other 10 patients had at least one well documented myocardial infarction. Vasodilators were discontinued for 72 hours and all diuretics were discontinued for 24 hours before the start of the study. Digoxin was discontinued for 12 hours before the study.

**HAEMODYNAMIC STUDY**

Each patient gave informed written consent. The right heart catheterisation was performed with a flow directed balloon tip, and a number 7 Swan–Ganz thermodilution catheter was inserted percutaneously through the right subclavian vein to record right atrial pressure (RAP), pulmonary arterial pressure (PAP), and pulmonary capillary wedge pressure (PCWP). We used the same catheter to measure cardiac output (CO) in triplicate by the thermodilution technique.

Arterial pressure was recorded directly by cannulating the radial artery. The haemodynamic variables were calculated as follows: SVI (ml/beat/m^2) = CO/HR/BSA, where SVI is stroke volume index, HR is heart rate, and BSA is body surface area; SWI (g m/min) = SVI × (MAP – PCWP) × 0.0136, where SWI is stroke work index, SVI is stroke volume index, MAP is mean arterial pressure, and PCWP is pulmonary capillary wedge pressure; SVR (dyn s cm^{-5}) = (MAP – RAP)/CO × 80, where SVR is systemic vascular resistance.

Under fluoroscopic guidance, a number 8 thermodilution coronary sinus flow catheter was placed in the coronary sinus through the left subclavian vein. To minimise the coronary sinus reflux the catheter was advanced under fluoroscopy into the mid-coronary sinus. Coronary sinus flow was measured by the constant infusion thermodilution technique. Coronary sinus flow in ml/min was calculated as [(Tb-Ti/Tb-Tm)] – 1 × 1.08 × 46 ml/min, where Tb is temperature of blood; Ti is temperature of injectate; Tm is temperature of mixture of blood and the injectate; 1.08 is a constant accounting for specific heart and density of both blood and indicator; and 46 ml/min is the injection rate of the indicator (5% dextrose in water) through the Harvard constant infusion pump.

Arterial and coronary sinus blood samples were drawn simultaneously for the determination of oxygen saturation, oxygen content, and lactate, adrenaline, and noradrenaline concentrations. Oxygen saturations were measured in duplicate by a Corning 158 pH and blood gas analyser. Lactate concentrations were measured by the enzymatic fluorometric method of Loomis, adrenaline and noradrenaline concentrations were measured by the radioenzymatic assay of Peuler and Johnson, and the renin concentrations were measured by the New England Nuclear Radioimmunoassay.

Oxygen content was calculated as oxygen saturation × haemoglobin × 1.34 and expressed in volume per cent. The arterial – coronary sinus oxygen difference (myocardial oxygen extraction) (ART – CS DO₂) was calculated as arterial oxygen content (ART O₂) – coronary sinus oxygen content (CS O₂). Myocardial oxygen consumption (MVO₂) was calculated as (ART – CS DO₂) × CSF (ml/min) × 10, and is expressed as ml of O₂ per min, where CSF is coronary sinus flow. Myocardial lactate extraction was calculated as (ART lactate – CS lactate)/(ART lactate) × 100, where ART lactate is arterial lactate concentration (mg/100 ml) and CS lactate is coronary sinus lactate concentrations. Transmyocardial noradrenaline values (pmol/min) were calculated as (coronary sinus noradrenaline – arterial noradrenaline) × coronary sinus blood flow (ml/min).

**DRUG DOSAGE**

Once the catheters were inserted, the first 10 patients received captopril in increasing doses (6.25, 12.5, 25, 50, 100 mg/day, base dose); and hydralazine + isosorbide dinitrate in increasing doses (10, 25, 50, 75 mg/day, base dose).

---

**Table 1** Changes in systemic haemodynamic function (mean (SD))

<table>
<thead>
<tr>
<th></th>
<th>Heart rate (beats/min)</th>
<th>Mean blood pressure (mm Hg)</th>
<th>Diastolic blood pressure (mm Hg)</th>
<th>PCWP (mm Hg)</th>
<th>Cardiac index (l/min/m²)</th>
<th>Stroke work index (gm/M²)</th>
<th>SVR (dyn s cm⁻⁵)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Captopril</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>94 (18)</td>
<td>92 (6)</td>
<td>72 (6)</td>
<td>26 (11)</td>
<td>2.1 (0.8)</td>
<td>2.3 (0.8)</td>
<td>1931 (627)</td>
</tr>
<tr>
<td>Peak</td>
<td>92 (19)</td>
<td>79 (11)†</td>
<td>61 (10)†</td>
<td>21 (9)</td>
<td>19 (5)</td>
<td>1459 (470)†</td>
<td></td>
</tr>
<tr>
<td>Hydralazine + isosorbide dinitrate:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>100 (11)</td>
<td>93 (16)</td>
<td>71 (5)</td>
<td>27 (6)</td>
<td>1.8 (0.3)</td>
<td>2.5 (0.3)†</td>
<td>2031 (470)</td>
</tr>
<tr>
<td>Peak</td>
<td>107 (12)†</td>
<td>77 (15)†</td>
<td>57 (12)†</td>
<td>21 (10)</td>
<td>17 (9)</td>
<td>1273 (505)†</td>
<td></td>
</tr>
</tbody>
</table>

* p < 0.05 vs control; † p < 0.01 vs control.

PCWP, pulmonary capillary wedge pressure; SVR, systemic vascular resistance.
50, 100, 150, and 200 mg) every hour (mean 180 mg, but seven of 10 patients responded at doses < 100 mg) until there was a > 10 mmHg decrease in mean arterial pressure, or the second dose of 200 mg of captopril was given. At this time a complete set of measurements was repeated. The next eight patients received a single 100 mg dose of hydralazine and, 90 min later, received 30 mg of oral isosorbide dinitrate. After another 30 min (120 min after the original hydralazine dose) a complete set of measurements was repeated.

Statistical Analysis
The effect of a vasodilator in any given patient was compared with baseline values by a two tailed paired t test. The change in any given variable caused by captopril was compared with that caused by the hydralazine-nitrate combination by a two tailed,

Fig 1  Systemic haemodynamic effects of captopril and hydralazine + isosorbide dinitrate in patients with severe congestive heart failure. Cardiac index increased in both groups of patients but the magnitude of increase was significantly greater in patients treated with hydralazine + isosorbide dinitrate. In both groups pulmonary capillary wedge pressure and systemic vascular resistance decreased to a similar extent. \( \Delta \), change from control; *p < 0.05 vs control. Values are mean (SE).

Fig 2  Relation between the percentage change in rate-pressure product and percentage change in myocardial oxygen consumption with captopril and with hydralazine + isosorbide dinitrate. The decrease in myocardial oxygen consumption with captopril parallels the decrease in the rate-pressure product, \( r = 0.81 \), whereas this relation varies with hydralazine + isosorbide dinitrate. Values for mean (SE) are shown.
Effects of captopril and hydralazine and isosorbide dinitrate on myocardial sympathetic tone

Table 2 Changes in coronary haemodynamic function (mean (SD))

<table>
<thead>
<tr>
<th></th>
<th>HR x BP (mm Hg/min x 10^-3)</th>
<th>CSF (ml/min)</th>
<th>ART - CS DO₂ (vol %)</th>
<th>MVO₂ (ml/min)</th>
<th>Lact extr (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Captopril:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>12.7 (2.6)</td>
<td>126 (45)</td>
<td>9.8 (1.4)</td>
<td>11.0 (5.1)</td>
<td>4 (18)</td>
</tr>
<tr>
<td>Peak</td>
<td>10.9 (2.5)</td>
<td>111 (39)*</td>
<td>9.6 (1.1)</td>
<td>9.6 (4.5)†</td>
<td>7 (9)</td>
</tr>
<tr>
<td>Hydralazine +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>isosorbide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dinitrate:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>14.1 (2.7)</td>
<td>106 (59)</td>
<td>10.1 (1.1)</td>
<td>9.9 (6.2)</td>
<td>18 (25)</td>
</tr>
<tr>
<td>Peak</td>
<td>12.7 (2.8)</td>
<td>94 (41)</td>
<td>9.0 (1.4)*</td>
<td>8.8 (4.0)</td>
<td>6 (26)</td>
</tr>
</tbody>
</table>

*p < 0.05 vs control; †p < 0.01 vs control.

HR x BP, rate-pressure product; CSF, coronary sinus blood flow; ART - CS DO₂, myocardial oxygen extraction; MVO₂, myocardial oxygen consumption; Lact extr, myocardial lactate extraction.

Table 3 Changes in myocardial sympathetic tone (mean (SD))

<table>
<thead>
<tr>
<th></th>
<th>Arterial noradrenaline (nmol/l)</th>
<th>Coronary sinus noradrenaline (nmol/l)</th>
<th>Transmyocardial noradrenaline (pmol/min)</th>
<th>Arterial adrenaline (nmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Captopril:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>4.2 (3.1)</td>
<td>7.0 (4.6)</td>
<td>390 (593)</td>
<td>0.63 (0.65)</td>
</tr>
<tr>
<td>Drug</td>
<td>3.9 (1.9)</td>
<td>6.3 (3.6)</td>
<td>317 (415)</td>
<td>0.60 (0.34)</td>
</tr>
<tr>
<td>Hydralazine +</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>isosorbide</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dinitrate:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>6.7 (5.7)</td>
<td>8.7 (8.2)</td>
<td>225 (484)</td>
<td>0.91 (0.58)</td>
</tr>
<tr>
<td>Drug</td>
<td>7.5 (7.3)</td>
<td>12.0 (11.4)*</td>
<td>554 (522)*</td>
<td>1.47 (0.75)†</td>
</tr>
</tbody>
</table>

*p < 0.05; †p < 0.01.

Results

SYSTEMIC HAEMODYNAMIC FUNCTION

Baseline systemic haemodynamic function in both groups was similar (table 1). Captopril and the hydralazine-nitrate decreased systemic arterial pressure and pulmonary capillary wedge pressure to a similar extent; however, hydralazine-nitrate caused a larger increase in cardiac index and stroke volume index than did captopril (table 1, fig 1). Only hydralazine-nitrate caused a statistically significant increase in heart rate.

Fig 3 Effects of captopril and hydralazine + isosorbide dinitrate on net cardiac noradrenaline balance. There was no change in cardiac noradrenaline release with captopril, whereas hydralazine + isosorbide dinitrate increased net myocardial noradrenaline release compared with control or captopril. Myocardial noradrenaline balance = coronary sinus - arterial noradrenaline concentration x coronary sinus flow. Values for mean (SE) are shown. *p < 0.05 vs control, †p < 0.05 vs captopril.

Fig 4 Change in arterial adrenaline concentration with captopril and hydralazine + isosorbide dinitrate. Hydralazine + isosorbide dinitrate increased arterial adrenaline whereas captopril had no effect. *p < 0.05 vs control, †p < 0.05 vs captopril.
CORONARY HAEMODYNAMIC FUNCTION
Captopril reduced the rate-pressure product, coronary sinuses blood flow, and global myocardial oxygen consumption (table 2, fig 2). Hydralazine-nitrate also tended to decrease the rate-pressure product, coronary sinus flow, and average myocardial oxygen consumption, but the changes were variable (table 2, fig 2) and not statistically significant (p > 0·1). Global myocardial lactate extraction did not change in either group.

MYOCARDIAL SYMPATHETIC ACTIVATION
Captopril had no effect on arterial catecholamines or on transmyocardial catecholamine balance, whereas the combination of hydralazine-nitrate increased both arterial adrenaline and net transmyocardial noradrenaline release (table 3, figs 3 and 4). The increase in transmyocardial noradrenaline release with the combination of hydralazine and isosorbide dinitrate was primarily due to an increase in coronary sinus noradrenaline concentrations.

Discussion
This study confirms the differences in the short term systemic and coronary haemodynamic effects of captopril and the combination of hydralazine-isosorbide dinitrate in patients with chronic heart failure.¹ ² Hydralazine-nitrate increases heart rate and cardiac index more than captopril does. With captopril the rate-pressure product fell consistently and myocardial oxygen requirements were reduced. There was a predictable decrease in myocardial oxygen consumption. With hydralazine-nitrate,² ³ however, no such relation was observed. The precise mechanism for these differences remains unclear; however, a reflex increase in myocardial sympathetic activation with hydralazine-nitrate that was not seen with captopril may provide a possible explanation.

This study demonstrated considerable differences in the short term effects of hydralazine-nitrates and captopril on circulating catecholamines and on transmyocardial catecholamine balance. With hydralazine-nitrate, arterial adrenaline increased and there was also a tendency for noradrenaline concentrations to be higher. Furthermore, the net transmyocardial release of noradrenaline increased in response to hydralazine-nitrate. With captopril, although the changes in circulating catecholamines and in transmyocardial catecholamine balance were not statistically significant, there was a tendency to lower arterial noradrenaline concentrations and decreased net transmyocardial noradrenaline release.

Because neither hydralazine nor isosorbide dinitrate has any direct effect on the sympathetic system,¹⁶ ⁻¹⁸ it is probable that the difference between these two regimens is the result of a direct neurohumoral effect of captopril on the sympathetic system.¹⁹ ⁻²¹ Converting enzyme inhibition reduces sympathetic activity in heart failure by attenuating the effects of angiotensin. Both hydralazine-nitrate and captopril reduced systemic arterial pressure; thus reflex activation of the sympathetic system should occur in response to both. It is likely, therefore, that captopril exerted a deactivating balancing influence on the sympathetic system, which probably resulted from its direct neurohumoral effect. With hydralazine-nitrate, reflex sympathetic activation remained unopposed. The observed differences in systemic and cardiac sympathetic activity in response to hydralazine-nitrate and captopril may have clinical relevance. The increase in heart rate and greater increase in stroke volume after hydralazine-nitrate may result from the reflex increase in sympathetic tone and contractility.

It has been suggested that an increase in the activity of circulating noradrenaline is associated with worse prognosis.²² It is possible, therefore, that the increase in cardiac sympathetic tone caused by the hydralazine-nitrate might have deleterious effects. Furthermore, an increase in sympathetic tone may activate the renin-angiotensin-aldosterone system and thus promote salt and water retention.

The mechanism by which captopril prevents cardiac sympathetic activation remains speculative; it is probably the result of attenuation of angiotensin II activity. Angiotensin II enhances sympathetic tone by central and peripheral mechanisms,¹⁹ ⁻²¹ and angiotensin II converting enzyme inhibitors have been shown to decrease hypoxia mediated noradrenaline release²³ and to decrease the circulating catecholamines in hypertensive patients.²⁴

This study has several limitations. First of all, these measurements were done with the patient in the supine position and there may be important differences between measurements taken while the patient is lying or standing.²⁵ Second, coronary sinus blood flow determinations do not allow assessment of changes in regional blood flow, and important differences in perfusion are likely to occur in the presence of coronary artery disease. Nevertheless, this study shows that there are important differences between the effects of captopril and hydralazine-nitrate on cardiac sympathetic tone, despite their similar haemodynamic effects. Further studies will be required to evaluate the clinical relevance of these findings.

This work was supported by the Department of Medicine of the Montreal General Hospital, the Quebec Heart Foundation, and Medical Research Council of Canada, and a grant from the Don and Daly, Rouleau, Cousineau, Burgess, Chatterjee
Effects of captopril and hydralazine and isosorbide dinitrate on myocardial sympathetic tone

Susan Schleicher Fund at the University of California, San Francisco.

References

Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure.

P Daly, J L Rouleau, D Cousineau, J H Burgess and K Chatterjee

*Br Heart J* 1986 56: 152-157
doi: 10.1136/hrt.56.2.152

Updated information and services can be found at:
http://heart.bmj.com/content/56/2/152

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/